Dew, Concerning P-Mab, just wondering what you now think of its chances of - 1) being approved and, 2) ultimately taking market share away from Erbitux? As we've seen, Amgen has high hopes for the drug, and they sound very confident. I see that P-Mab has a dosing advantage over Erbitux (dosed every other week vrs weekly dosing), plus there's no need for premedication, and it has a very low incidence of infusion reactions. Plus Amgen can bundle it with their other cancer drugs to help with market penetration. I remember you mentioning that reimbursment might be a challenge for P-Mab, and that Erbitux has the advantage of having more varied clinical data supporting its use. Just curious to get your current take on P-Mab. (My interest in it lies primarily with Abgenix and their 50% ownership). Thanks Dew.
